Abstract
Alzheimers disease (AD) is an incurable age-related neurodegenerative disorder characterized by profound memory dysfunction. This bellwether symptom suggests involvement of the hippocampus -- a brain region responsible for memory formation -- and coincidentally an area heavily burdened by hyperphosphorylated tau and neuritic plaques of amyloid beta (Aβ). Recent evidence suggests that pre-fibrillar soluble Aβ underlies an early, progressive loss of synapses that is a hallmark of AD. One of the downstream effects of soluble Aβ aggregates is the activation of the phosphatase calcineurin (CaN). This review details the evidence of CaN hyperactivity in ‘normal’ aging, models of AD, and actual disease pathogenesis; elaborates on how this could manifest as memory impairment, neuroinflammation, hyperphosphorylated tau, and neuronal death.
Keywords: Alzheimers, amyloid beta, calcineurin, calcium, pre-fibrillar soluble A, glycogen synthase kinase-3 beta (GSK-3 ), voltage-gated sodium (Na+), neurotransmitter, Ca2+ fluctuation
Current Neuropharmacology
Title: A Role for Calcineurin in Alzheimers Disease
Volume: 9 Issue: 4
Author(s): Lindsay C. Reese and Giulio Taglialatela
Affiliation:
Keywords: Alzheimers, amyloid beta, calcineurin, calcium, pre-fibrillar soluble A, glycogen synthase kinase-3 beta (GSK-3 ), voltage-gated sodium (Na+), neurotransmitter, Ca2+ fluctuation
Abstract: Alzheimers disease (AD) is an incurable age-related neurodegenerative disorder characterized by profound memory dysfunction. This bellwether symptom suggests involvement of the hippocampus -- a brain region responsible for memory formation -- and coincidentally an area heavily burdened by hyperphosphorylated tau and neuritic plaques of amyloid beta (Aβ). Recent evidence suggests that pre-fibrillar soluble Aβ underlies an early, progressive loss of synapses that is a hallmark of AD. One of the downstream effects of soluble Aβ aggregates is the activation of the phosphatase calcineurin (CaN). This review details the evidence of CaN hyperactivity in ‘normal’ aging, models of AD, and actual disease pathogenesis; elaborates on how this could manifest as memory impairment, neuroinflammation, hyperphosphorylated tau, and neuronal death.
Export Options
About this article
Cite this article as:
C. Reese Lindsay and Taglialatela Giulio, A Role for Calcineurin in Alzheimers Disease, Current Neuropharmacology 2011; 9 (4) . https://dx.doi.org/10.2174/157015911798376316
DOI https://dx.doi.org/10.2174/157015911798376316 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Ion Channels, Cellular Carriers and Na(+)/K(+)/ATPase by Janus Kinase 3
Current Medicinal Chemistry Recent Advances and Patents for Nerve Scaffold Biomaterials and their Use for Local, Non-Viral Delivery of Growth Factors and Nucleic Acids
Recent Patents on Biomedical Engineering (Discontinued) Anti-Oxidative Polyphenolic Compounds of Cocoa
Current Pharmaceutical Biotechnology Ketogenic Diet and Other Dietary Intervention Strategies in the Treatment of Cancer
Current Medicinal Chemistry Epigenomic Approach in Understanding Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Ultrasonic Vocalizations in Rats: A Tool for the Investigation of Psychoactive Drugs and Neuropsychiatric Conditions)
Current Neuropharmacology Editorial (Thematic Issue: Induced Cell-Based Transplantation to Therapeutically Target Spinal Cord Disorders)
Current Stem Cell Research & Therapy Molecular Dynamic Study of Human Prion Protein upon D178N Mutation: New Perspective to H-bonds, Salt Bridges and the Critical Amino Acids
Protein & Peptide Letters The Effect of Acori Graminei Rhizoma and Extract Fractions on Spatial Memory and Hippocampal Neurogenesis in Amyloid Beta 1-42 Injected Mice
CNS & Neurological Disorders - Drug Targets Challenges and Advances in Gene Therapy Approaches for Neurodegenerative Disorders
Current Gene Therapy Dopamine Agonists in the Treatment of Parkinsons Disease-Past, Present and Future
Current Pharmaceutical Design A New Hypothesis of Pathogenesis Based on the Divorce between Mitochondria and their Host Cells: Possible Relevance for Alzheimers Disease
Current Alzheimer Research C-Abl Inhibition; A Novel Therapeutic Target for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease
Current Neuropharmacology Vitamin E and All-Cause Mortality: A Meta-Analysis
Current Aging Science Polyglutamine Protein Trafficking and Neurodegeneration
Current Genomics 6-Acetyl-5H-thiazolo[3,2-a]pyrimidine Derivatives as the Novel Acetylcholinesterase Inhibitors: Design, Synthesis, and Biological Activity
Medicinal Chemistry Nanoparticles, Neurotoxicity and Neurodegenerative Diseases
Current Drug Metabolism Calcium Homeostasis Following Traumatic Neuronal Injury
Current Neurovascular Research Pharmacodynamics of Memantine: An Update
Current Neuropharmacology